Evaluation of the tumor load and adverse reactions of nedaplatin combined with paclitaxel liposome and with paclitaxel treatment of advanced esophageal cancer

• Main Authors: Jun-Ying Liang1, Mao-Nan Yang2
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2017-04-01
• Series: Journal of Hainan Medical University
• Subjects: Advanced esophageal cancer Paclitaxel liposome Paclitaxel Tumor load Adverse effects
• Online Access: http://www.hnykdxxb.com/PDF/201708/27.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To evaluate the tumor load and adverse reactions of nedaplatin combined with paclitaxel liposome and with paclitaxel treatment of advanced esophageal cancer. Methods: A total of 68 patients with advanced esophageal cancer who were treated in our hospital between August 2013 and March 2016 were collected and divided into the paclitaxel liposome group (n=34) who received nedaplatin combined with paclitaxel liposome therapy and the paclitaxel group (n=34) who received nedaplatin combined with paclitaxel therapy according to the double-blind randomized control method, and both therapies lasted for 8 weeks. Before treatment and after 8 weeks of treatment, RIA method was used to determine serum esophageal cancer-related tumor marker levels, enzyme-linked immunosorbent assay was used to determine serum angiogenesis index levels, and flow cytometry was used to measure cellular immunity indexes. Results: Before treatment, the differences in serum tumor marker and angiogenesis index levels as well as cellular immune function indexes were not statistically significant between the two groups. After 8 weeks of treatment, serum tumor markers CY211, CEA, SCC, CA724 and CA125 levels of observation group were lower than those of control group, angiogenesis indexes HIF-α, VEGF and MMP-9 levels were lower than those of control group, and peripheral blood cellular immunity indexes CD4+ and CD4+/CD8+ levels were higher than those of control group while CD8+ level was lower than that of control group. Conclusion: Nedaplatin combined with paclitaxel liposome can more effectively reduce the tumor load, causes less adverse effects, and has good curative effect and security.